Valneva Slashes Staff and Outlook as Travel Vaccine Slump Deepens, But Lyme Shots Keep Pipeline Afloat

The mood in travel medicine has soured, and few companies feel the chill more acutely than Valneva. The French vaccine developer saw its first-quarter revenue slide 37% year-on-year to €30.9 million, dragged down by a cocktail of geopolitical tension and tepid demand for pre-travel jabs. The damage forced management to move quickly: a 10%–15% reduction in the global workforce and a downgraded full-year forecast that now targets product sales of just €135 million to €150 million.

Behind the top-line disappointment lies a sharper sting in the bottom line. Net losses nearly tripled to €32.1 million in the three months through March, hurt in part by one-off charges related to contract terminations. Valneva’s own-brand vaccines — the Japanese encephalitis shot Ixiaro and the cholera vaccine Dukoral — generated €20 million and €8.6 million respectively, but that was not enough to offset a deliberate scale-back in distribution of third-party products and a broader travel slump.

Austerity and a capital lifeline

The cost-cutting campaign aims to slash operating expenses by up to 35% versus last year. Valneva ended March with roughly €105 million in cash and equivalents, a cushion that was supplemented in early May by an €84 million capital increase. That fresh money is earmarked for R&D, primarily the marquee Lyme disease programme VLA15, which Valneva is co-developing with Pfizer.

Should investors sell immediately? Or is it worth buying Valneva?

Phase 3 data for that candidate showed efficacy exceeding 70%, even though it narrowly missed a secondary statistical endpoint. Pfizer has nonetheless begun preparing regulatory submissions, a step that will define Valneva’s commercial trajectory. Additional pipeline catalysts include readouts from the Shigella vaccine programme in the coming months and an ongoing rollout of the Chikungunya vaccine, which has already reached tens of thousands of people in Brazil. North American commercialisation, however, continues to wrestle with logistical hurdles.

Analyst sniping and a battered chart

The weak operational performance has drawn sharp rebukes from the sell side. Several investment banks have cut their ratings to “Sell,” pointing to Valneva’s failure to keep pace with the broader biotech rally. The average price target has slid to €5.28, while the stock itself trades at €2.55 — a year-to-date decline of roughly 34% that leaves it hovering near its early-May trough. The discount to the 200-day moving average stands at more than 34%, underscoring a stubborn downward trend.

For now, Valneva’s near-term story is one of triage: trim costs, preserve cash, and wait for the next pivotal readout. The Lyme vaccine filing will be the clearest signal yet of whether the company’s pipeline can outrun its commercial headwinds.

Ad

Valneva Stock: New Analysis - 15 May

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA | boerse | 69343412 |